Notably, HER2 knockdown increased the inhibitory effect of CDK4/6 inhibitor combined with endocrine therapy on the proliferation of HR+/HER2-low breast cancer cells, as demonstrated by CCK-8 and colony formation assays (P < 0.05) (Fig. 3C,D). This evidence concerns the gene ERBB2 and breast carcinoma.